We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

78 hedge funds and large institutions have $135M invested in Praxis Precision Medicines in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

212% more capital invested

Capital invested by funds: $43.1M → $135M (+$91.5M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

1.1% less ownership

Funds ownership: 6.77% → 5.68% (-1.1%)

9% less funds holding

Funds holding: 86 → 78 (-8)

24% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 25

27% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 30

Holders
78
Holders Change
-8
Holders Change %
-9.3%
% of All Funds
1.22%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
22
Increased
19
Reduced
25
Closed
30
Calls
$51K
Puts
–
Net Calls
+$51K
Net Calls Change
+$238K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$10.7M
2
CAM
Cormorant Asset Management
Massachusetts
+$9.7M
3
SFM
Sphera Funds Management
Israel
+$8.95M
4
Verition Fund Management
Verition Fund Management
Connecticut
+$7.68M
5
PHS
PFM Health Sciences
California
+$6.85M

Top Sellers

1
APM
Avidity Partners Management
Texas
-$3.46M
2
BlackRock
BlackRock
New York
-$2.33M
3
GPP
Great Point Partners
Connecticut
-$1.64M
4
State Street
State Street
Massachusetts
-$774K
5
Goldman Sachs
Goldman Sachs
New York
-$620K
Name Holding Trade Value Shares
Change 		Change in
Stake
7IH
26
72 Investment Holdings
Connecticut
$1.14M – – –
SSA
27
Schonfeld Strategic Advisors
New York
$828K +$192K +12,543 +35%
HMC
28
Harvard Management Company
Massachusetts
$797K -$87.7K -5,727 -11%
Citadel Advisors
29
Citadel Advisors
Florida
$758K +$36.1K +2,361 +6%
Renaissance Technologies
30
Renaissance Technologies
New York
$754K +$282K +18,387 +73%
BlackRock
31
BlackRock
New York
$695K -$2.33M -152,290 -79%
UOC
32
UBS O'Connor
Illinois
$671K +$77.9K +5,086 +15%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$510K -$400K -26,152 -47%
Federated Hermes
34
Federated Hermes
Pennsylvania
$421K -$22.5K -1,472 -6%
JGC
35
J. Goldman & Co
New York
$311K +$138K +9,000 +100%
Morgan Stanley
36
Morgan Stanley
New York
$279K -$598K -39,036 -71%
State Street
37
State Street
Massachusetts
$242K -$774K -50,531 -78%
Goldman Sachs
38
Goldman Sachs
New York
$177K -$620K -40,477 -80%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$174K +$48.3K +3,155 +45%
Northern Trust
40
Northern Trust
Illinois
$139K -$292K -19,047 -70%
BCM
41
Bridgeway Capital Management
Texas
$117K -$55.2K -3,607 -35%
CH
42
CVI Holdings
Delaware
$103K +$91K +5,945 New
Qube Research & Technologies (QRT)
43
Qube Research & Technologies (QRT)
United Kingdom
$87.1K +$77.3K +5,049 New
TCM
44
Tekla Capital Management
Massachusetts
$86.3K – – –
PI
45
PEAK6 Investments
Illinois
$85.6K -$15.3K -1,000 -17%
YIH
46
Y-Intercept (HK)
Hong Kong
$77.3K +$68.6K +4,478 New
Connor, Clark & Lunn Investment Management (CC&L)
47
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$44.5K +$39.5K +2,580 New
Principal Financial Group
48
Principal Financial Group
Iowa
$36.5K +$13K +847 +67%
AWA
49
Alta Wealth Advisors
Massachusetts
$35.7K – – –
OMC
50
Old Mission Capital
Illinois
$28.8K +$25.6K +1,669 New
1
2
3 4 5

PRAX Hedge Fund Activity: Q2 2023 in Review

78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q2 2023, worth a combined $135M — up 212% from $43.1M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PRAX and 22 opened new positions — a net loss of 8 holders — while 25 trimmed existing stakes and 19 added.

The largest buyer was Point72 Asset Management, adding an estimated $10.7M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $3.46M sold.

  • 78 institutional investors held Praxis Precision Medicines (PRAX) as of Q2 2023, down from 86 in Q1 2023.
  • Funds reported $135M of Praxis Precision Medicines stock for Q2 2023, up 212% quarter-over-quarter.
  • 22 funds opened new Praxis Precision Medicines positions in Q2 2023 and 30 closed out, a net change of -8 holders.
  • The largest Praxis Precision Medicines buyer in Q2 2023 was Point72 Asset Management, an estimated $10.7M added.
  • The largest Praxis Precision Medicines seller in Q2 2023 was Avidity Partners Management, an estimated $3.46M sold.

Based on aggregated 13F filings for Q2 2023.